Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $7,159 | $6,486 | $6,789 | $5,447 |
| - Cash | $385 | $458 | $534 | $850 |
| + Debt | $4,515 | $4,844 | $4,382 | $4,345 |
| Enterprise Value | $11,289 | $10,872 | $10,638 | $8,943 |
| Revenue | $4,582 | $4,264 | $4,027 | $3,569 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Gross Profit | $3,001 | $2,832 | $2,783 | $2,462 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| EBITDA | $1,211 | $1,144 | $1,284 | $1,183 |
| % Margin | 26.4% | 26.8% | 31.9% | 33.2% |
| Net Income | $108 | $144 | $317 | $230 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS Diluted | 33.62 | 45.58 | 100.97 | 72.94 |
| % Growth | -26.2% | -54.9% | 38.4% | – |
| Operating Cash Flow | $1,057 | $716 | $977 | $1,123 |
| Capital Expenditures | -$201 | -$481 | -$634 | -$186 |
| Free Cash Flow | $856 | $236 | $343 | $937 |